Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Perioperative Enfortumab Vedotin and Pembrolizumab May Be Cost-Effective in Bladder Cancer

A JAMA Network Open economic model found perioperative enfortumab vedotin plus pembrolizumab improved survival and was likely cost-effective for cisplatin-ineligible MIBC.

By Dr. Revathy Mohan V.R., MBBS · Nov 1, 2026 · 5 min read

Oncology·JAMA Open

Darolutamide in Metastatic Prostate Cancer: ARANOTE Subgroup Analysis

Post hoc ARANOTE analysis examines darolutamide plus ADT by disease volume and risk in metastatic hormone-sensitive prostate cancer.

Nov 1, 2026

Oncology·Gut

Gastric Cancer Atlas Links C/EBPβ to Liver Metastasis

A multisite metastatic atlas of gastric cancer identifies C/EBPβ as a regulator of liver spread, pointing to a…

Oct 31, 2026

Oncology·Gut

Endoscopic Resection After Neoadjuvant Therapy in Rectal Cancer Case Series

A multicentre rectal cancer case series examines endoscopic resection after neoadjuvant therapy in patients with near-complete response and…

Oct 31, 2026

Oncology·EHJ

lung cancer tracking under UK Department of Health targets

Insufficient source text to confirm study methods or results, but the title points to UK lung cancer tracking…

Oct 31, 2026

Oncology·EHJ

ORR4 may track prognosis in mogamulizumab-treated cutaneous T-cell lymphoma

An academic analysis examines ORR4 as an on-treatment prognostic marker in mogamulizumab-treated mycosis fungoides and Sézary syndrome.

Oct 31, 2026

Oncology·ACC-PRO

Roche launches BAP1 test for mesothelioma differential diagnosis

Roche has launched a BAP1 immunohistochemistry assay to help pathologists distinguish mesothelioma from other cancers while preserving scarce…

Oct 31, 2026

Oncology·Nature

Pembrolizumab Cost-Effectiveness in Platinum-Resistant Ovarian Cancer Falls Short

A Markov model found pembrolizumab plus paclitaxel was not cost-effective for platinum-resistant recurrent ovarian cancer at current prices.

Oct 31, 2026

Oncology·JCI

NKG2D Attenuation Boosts NK Cell Persistence in Solid Tumors

Lowering NKG2D stimulation reshaped intratumoral NK cells, preserved stem-like function, and improved persistence after adoptive transfer in solid…

Oct 31, 2026

Oncology·BBC Dental

Neuroblastoma vaccine trial offers family hope for toddler Teddy Sloman

Teddy Sloman, 3, is heading to New York for a neuroblastoma vaccine trial after scans showed no active…

Oct 31, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.